PharmaCyte Biotech (PMCB) EBITDA (2010 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly EBITDA of -$2.5 million for Q2 2026, down 141.03% year-over-year from $6.1 million in Q2 2025, and down 18.56% quarter-over-quarter from -$2.1 million in Q1 2026.
PharmaCyte Biotech (PMCB) EBITDA (2010 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported EBITDA for 17 consecutive years, with -$2.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, EBITDA fell 141.03% year-over-year to -$2.5 million; the TTM figure through Apr 2026 stood at -$6.9 million (down 56.58% YoY), while the FY2026 annual figure was -$6.9 million, down 56.55% from the prior year.
- EBITDA slipped to -$2.5 million in Q2 2026 per PMCB's latest filing, from -$2.1 million in the prior quarter.
- Across five years, EBITDA topped out at -$848305.0 in Q3 2025 and bottomed at -$3.2 million in Q2 2024.
- Historically, EBITDA has averaged -$1.6 million across 5 years, with a median of -$1.5 million in 2022.
- Annual changes were most pronounced in 2024 — EBITDA sank 250.52% — and 2025, when it surged 67.09%.
- PharmaCyte Biotech's EBITDA stood at -$2.3 million in 2022, then soared by 39.21% to -$1.4 million in 2023, then advanced by 21.53% to -$1.1 million in 2024, then decreased by 24.41% to -$1.4 million in 2025, then tumbled by 82.5% to -$2.5 million in 2026.
- Business Quant data shows PMCB's EBITDA at -$2.5 million in Q2 2026, -$2.1 million in Q1 2026, and -$1.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | PharmaCyte Biotech | 4.30 Mn | 4.30 Mn | - | -2.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -2.51 Mn |
| Jan 31, 2026 | -2.12 Mn |
| Oct 31, 2025 | -1.38 Mn |
| Jul 31, 2025 | -848,305.00 |
| Apr 30, 2025 | -1.04 Mn |
| Jan 31, 2025 | -960,252.00 |
| Oct 31, 2024 | -1.11 Mn |
| Jul 31, 2024 | -1.27 Mn |
| Apr 30, 2024 | -3.17 Mn |
| Jan 31, 2024 | -1.87 Mn |
| Oct 31, 2023 | -1.41 Mn |
| Jul 31, 2023 | -2.08 Mn |
| Apr 30, 2023 | -903,283.00 |
| Jan 31, 2023 | -1.55 Mn |
| Oct 31, 2022 | -2.32 Mn |
| Jul 31, 2022 | -1.68 Mn |
| Apr 30, 2022 | -1.51 Mn |
| Jan 31, 2022 | -856,119.00 |
| Oct 31, 2021 | -1.00 Mn |
| Jul 31, 2021 | -1.02 Mn |